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Obesity was identified as a risk factor for severe influenza during the 2009 influenza
A(H1N1)pandemic, but evidence of this association has been mixed since. Post-
pandemic antiviral treatment guidelinesmay have increased antiviral treatment among
obese individuals. A prospective study of adults hospitalized with laboratory-
confirmed influenza in Detroit, Michigan in 2011-2012 and 2012-2013 was
conducted. Patient information was collected from interviews and medical chart
abstraction. Obese (BMI ≥ 30) and non-obese (BMI < 30) participants were compared.
Late antiviral treatment (>2 days from symptom onset), obesity (30 ≤ BMI < 40), and
morbid obesity (BMI ≥ 40) were evaluated as predictors of lower respiratory tract
disease (LRD), ICU admission, and length of stay (LOS) using logistic regression and
inverse probability weighted models. Forty-eight participants were included in the
study after exclusions and all patients received antiviral treatment. Participants who
were obese were significantly more likely to have a cough and to take steroids than
non-obese participants, and had a shorter time from hospital admission to antiviral
treatment (median time from admission to treatment of 0 days for obese patients and
1 day for non-obese patients [P = 0.001]). In all models, late antiviral treatment was
associatedwith increasedoddsof LRD (OR: 3.9 [1.1,15.9] in fully adjustedmodel). After
adjustment for treatment timing, the odds of ICU admission (OR: 6.4 [0.8,58.2] to 7.9
[0.9, 87.1]) and LRD (OR: 3.3 [0.5, 23.5] to 4.0 [0.6, 35.0]) associated with morbid
obesity increased. Obese individuals were treated with antivirals earlier than others.
Late antiviral treatment was associated with severe influenza in the hospital.
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1 | INTRODUCTION
Influenza virus, though usually a self-limiting infection, is associated
with increased morbidity and mortality during annual outbreaks.1 In
general, older adults and individuals with underlying comorbid
conditions are at high risk for adverse events after influenza infection.2
In 2009, the emergence of the 2009 pandemic influenza A(H1N1) virus
lead to an increased prevalence of severe outcomes among
populations that had not previously been considered at high risk for
these consequences of disease. Specifically, children and young adults
were more likely to be hospitalized for influenza; and morbid obesity
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(body mass index of 40 or greater) was identified as a predictor of
hospitalization, ICU admission, and of death.3–5
Subsequent analyses using data from non-pandemic influenza
seasons have left an unresolved picture of the relationship between
obesity and influenza severity and whether this relationship persists
beyond the influenza A(H1N1)pdm09 subtype. A study by Cocoros
et al. regarding seasonal and pandemic influenza A(H1N1) found that
obesity had a small association with severe influenza like illness (ILI) in
seasons dominated by H1N1 before and after the 2009 pandemic,
leading to hospitalization.6 However, these results were only seen in
certain age groups in the study population and these results have not
been consistently validated in other populations.7,8
Differences in antiviral treatment timing add further complexity to
this issue in the post-pandemic period. A meta-analysis analyzing the
relationship between obesity and influenza A(H1N1)pdm09 severity
in 2009-2011 influenza seasons globally found that the significant
relationship between obesity and influenza complications was
attenuated and non-significant after adjustment for antiviral prescrip-
tion timing; the authors found that obese individuals were less likely to
receive antivirals in a timely fashion and that this treatment timing was
an important confounder of the relationship between obesity and
influenza severity.9 However, in the United States, a recent change to
antiviral treatment recommendations may have altered this relation-
ship between treatment timing and weight status. After review of data
from the 2009 pandemic, the Center for Disease Control and
Prevention (CDC) added morbid obesity to their list of indicators for
high influenza severity risk and recommended that these individuals be
prescribed antiviral treatment empirically in the outpatient setting.10
These recommendations may lead physicians to treat hospitalized
obese patients earlier than patients without a high-risk condition,
either through empiric treatment in outpatient settings before
presentation to the hospital, or through immediate treatment upon
hospital admission. Previous studies have demonstrated that treat-
ment with oseltamivir within 48 h of symptom onset reduces severe
complications of influenza and that oseltamivir is most effective when
given within 48 h.11,12 However, oseltamivir is also associated with
reduced duration of shedding when it is given within 72 h of symptom
onset, and increased survival and decreased severity for up to 5 days
after illness onset.13–15 If obese individuals are treated earlier than
others, antiviral receipt timing may complicate the ability to detect an
association between obesity and influenza severity.
In order to evaluate the relationship between antiviral timing,
obesity, and influenza severity, a prospective study of hospitalized
influenza-positive adults in Detroit, Michigan was conducted. A
previous study in this region found that nearly 50% of the study
population had a body mass index (BMI) classified as obese, well over
the state average of 30.7%.16 The results of this study indicated that
obese individuals were more likely than non-obese individuals to be
admitted to inpatient care, to have hospital stays of greater than
7 days, and to have lower respiratory tract disease manifestations,
following influenza infection, predominately with influenza A(H1N1)
pdm09.17 The aim of this current study is to use a prospective design
and data from the2011 to 2012 and 2012 to 2013 influenza seasons to
expand on the previous data linking obesity to influenza severity, and
to evaluate the role of the timing of antiviral administration in this
association.
2 | METHODS
2.1 | Study population
Hospitalized adults admitted to one of five Detroit, Michigan area
hospitals with laboratory confirmed influenza from February through
April 2012 and November 2012 through March 2013 were
prospectively identified. Participants were enrolled from Detroit
Receiving Hospital, Harper Hospital, Hutzel Women's Hospital,
Sinai-Grace Hospital, and Henry Ford Hospital. Patients were
identified from a clinical microbiology laboratory results using a
clinical alert system (Theradoc) and their eligibility status was
confirmed with their treating physician. Patients admitted to the
hospital were eligible if they were 18 years old or greater, and if they
tested positive for influenza A (H1N1)pdm09, influenza A (H3N2), or
influenza B, and if they had any symptom compatible with influenza
like illness (ILI) including cough, chills, rhinorrhea, myalgia, dyspnea,
diarrhea, vomiting, and/or subjective fever. Patients were excluded
from the analysis if they had symptom duration longer than 10 days
before admission and if they had a BMI less than 18.5. Eligible patients
were approached for informed consent.
2.2 | Participant survey and data abstraction
After affirmative consent, patients were surveyed to determine their
illness onset date, physical characteristics, alcohol and smoking
histories, living situation, and influenza and pneumococcal vaccine
information. There were also asked about any physical, mental, or
emotional limitations and if they routinely used special equipment due
to a health problem (i.e. wheelchair, cane, special bed, special
telephone). All day 1 interview questions were adapted from the
Centers for Disease Control and Prevention Behavioral Risk Factor
Surveillance System Survey Questionnaire.18 Additional information
regarding demographics, insurance information, and medical informa-
tion pertaining to symptoms, admission timing, antiviral and antibiotic
therapy, vaccination, readmission, ICU admission, laboratory results,
virus testing results, diagnoses, and comorbidities was collected from
the electronic medical record (EMR). Specific conditions evaluated
were a history of cancer, lung disease (bronchiectasis, COPD/
emphysema, asthma, restrictive disease, interstitial lung disease),
history of heart conditions (myocardial infarction, coronary artery
disease, coronary artery bypass grafting), diabetes, renal disease, and
HIV. Steroid use, including use of glucocorticoid steroids, prednisone,
or methylprednisolone in the last month, was also abstracted from the
EMR. The patients were interviewed again by phone 30 days after
enrollment to collect information on any new hospital admissions and
the reason for these visits as well as any visit to a doctor in a doctor's
office and the reason for these visits. Information on medications
prescribed since discharge was also collected and patients were asked
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whether they had made diet or exercise changes since their discharge
date.
2.3 | Statistical analysis
Severe outcomes in this study were defined as ICU admission, lower
respiratory tract disease (intubation, hypoxia, lung infiltrates, or
consolidation) and increased length of stay. For the determination of
lower respiratory tract disease, hypoxia was defined as oxygen
saturation percentage marked as abnormal (below 94%), and lung
infiltrates as well as consolidation were defined by a description of
infiltrates or consolidation on chest X-ray impressions. In frequency
models, obese (BMI of 30 or greater) and non-obese (BMI less than 30)
participants were compared; P values were determined using Fisher's
exact tests. Differences in distributions of continuous variables were
tested using the Wilcoxon rank-sum test. Unadjusted and adjusted
Firth-penalized logistic models were run to predict odds of severity;
unadjusted models contain either categorical BMI (BMI less than 30,
BMI of 30 to less than 40, BMI of 40 or greater) or dichotomized
antiviral treatment timing (late treatment defined as >2 days from
symptom onset), adjusted models contained both variables. Inverse
probability weighting (IPW) of propensity scores was used to
efficiently adjust for age, diabetes, and poor/fair self rated health
despite the small sample size. Diabetes was deemed the most
important clinical confounder due to the impact of immune system
disruption on influenza outcomes and to the recommendations that
antivirals be used promptly in these patients.19,20 Asthma was not
included in the model because it did not improve model fit. IPW of
propensity scores was used to reduce bias in effect estimates by
balancing the baseline characteristics between those with and without
the outcome of interest. Due to collinearity between steroid use and
other elements in the model it was not used as an adjustment factor.
For the outcome of increased length of stay, length of stay was log-
transformed and linear regression was used to predict percentage
change in length of stay. All statistics were run on SAS 9.4 (Statistical
Analysis System).
3 | RESULTS
There were 55 individuals enrolled in this study with laboratory-
confirmed influenza. Individualswere excluded if they hadmissing data
on BMI, lower respiratory tract disease, or ICU admission. Additionally,
individuals who reported symptom onset of greater than 10 days
before admission were excluded. The final analysis was performed on
the 48 individuals with complete data. All (N = 48) participants were
treatedwith oseltamivir, three of these patientswere given oseltamivir
1 day before their study admission. Of these 48 participants, 34
(70.8%) completed the 30-day follow up survey.
Twenty-four (50%) participants were obese and five (10.4%) were
morbidly obese. The median age was 54.5 years of age in obese
individuals and 60.5 years of age in non-obese individuals. Obese
individuals had significantly shorter duration from admission to
antiviral therapy and significantly greater frequency of steroid
prescription in the prior three months (Table 1). At study enrollment,
approximately 50% (n = 23) of participants self-reported the need for
special equipment due to a health problem, almost (n = 28) 60%
reported having physical, mental, or emotional limitations, over 50%
(n = 25) reported poor/fair health, and nearly 80% (n = 37) reported
having shortness of breath that affects their quality of life. All of these
self-reported health conditions were more common among obese
patients, though these differences were not statistically significant
(Table 2). Fifty percent (n = 24) of participants reported receiving an
influenza vaccine in the last year and 62.5% (n = 30) reported receiving
a pneumococcal vaccine during their lifetime (Table 2).
Thirty-four individuals participated in the survey given approxi-
mately 1 month post-discharge. 79.4% (n = 26) of individuals reported
having an appointment with their primary care physician, 15 (57.7%) of
these appointments were follow up appointments and 20.5% (n = 7)
reported being readmitted to the hospital within 30-days of hospital
discharge. Reasons for readmission included deep vein thrombosis,
chest pain and coronary artery disease, pneumonia, ischemic
cardiopathy, chronic obstructive pulmonary disease exacerbation,
and congestive heart failure exacerbation. Almost 70% (n = 26) of
participants reported receiving a new prescription at discharge and
nearly 70% (n = 17) of those who received a prescription completed
the full dose of the new medication. A variety of medications were
prescribed in the 30 days post-discharge including antibiotics,
antivirals, steroids (inhaled and ingested), blood pressure medication,
pain medication, and blood thinners, among others. Over half (52.9%,
n = 18) of participants reported making a positive change to their diet
or exercise habits 30-days after hospital discharge (Table 3). There
were no deaths within 30 days of discharge.
In univariate models, late antiviral treatment was significantly
associated with increased odds of lower respiratory tract disease and
increased length of hospitalization (OR: 3.6 [1.1, 14.2], Percent change:
40.8 [2.6, 93.2]) (Table 4). After adjustment for BMI group, the odds of
lower respiratory tract disease and ICU admission associated with late
antiviral treatment increased in magnitude. In the IPW models the
association between late antiviral treatment and lower respiratory
tract disease remained significant (OR: 3.9 [1.1, 15.9]).
In the univariate model, obese individuals (BMI from 30 to less
than 40) had significantly shorter length of hospitalization than non-
obese individuals (Percent change: −29.2 [−49.6, −0.6]) (Table 4).
Obesity and morbid obesity were also associated with increased odds
of ICU admission and lower respiratory tract disease, and these
relationships were monotonic, though not significant (Table 4). After
adjustment for late-antiviral treatment the odds of lower respiratory
tract disease and ICU admission increased in the obese group, though
they did not reach statistical significance.
4 | DISCUSSION
This study demonstrated that antiviral treatment within two days of
symptom onset was associatedwith reduced odds of lower respiratory
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TABLE 1 Patient characteristics by obesity status
Characteristics Total (N = 48) BMI ≥ 30 (N = 24) BMI < 30 (N = 24) P-value*
Age (median, range) 59.0 (21-91) 54.5 (21-83) 60.5 (21-91) 0.30
BMI (mean, 95%CI) 30.3 (27.6, 33.0) — — —
Days from admission to antiviral
treatment (median, rangea)
0.0 (0.0-6.0) 0.0 (0.0-4.0) 1.0 (0.0-6.0) 0.001
N (% of total) N (% of obese) N (% of not obese) P-value**
Female sex 23 (47.9) 11 (45.8) 12 (50.0) 0.77
Raceb 0.45
White 5 (10.6) 2 (8.7) 3 (12.5)
Black 39 (83.0) 21 (91.3) 18 (75.0)
Other 3 (6.4) 0 (0.0) 2 (8.3)
Symptoms
GI symptoms 20 (41.7) 7 (29.2) 13 (54.2) 0.08
Cough 37 (77.1) 22 (92.1) 15 (62.5) 0.02
Fever 26 (54.2) 15 (62.5) 11 (45.8) 0.25
Chills 22 (45.8) 13 (54.2) 9 (37.5) 0.25
Shortness of breath 29 (60.4) 17 (70.8) 12 (50.0) 0.14
Fatigue 12 (25.0) 4 (16.7) 8 (33.3) 0.18
Clinical factors
Diabetes 16 (31.2) 8 (33.3) 7 (29.2) 0.76
Chronic obstructive pulmonary disease 11 (22.9) 7 (29.2) 4 (16.7) 0.30
Asthma 8 (16.7) 5 (20.8) 3 (12.5) 0.44
Congestive heart failure 11 (22.9) 5 (20.8) 6 (25.0) 0.73
Sepsis 20 (41.7) 11 (45.8) 9 (37.5) 0.56
Steroid usec 13 (27.7) 10 (43.5) 3 (12.5) 0.02
aThree obese patients were given oseltamivir 1 day before admission, these individuals were classified as treated 0 days from hospital admission.
bOne individual with obesity is missing race status.
cOne individual with obesity is missing information on steroid medication.
*P values are the result of Wilcoxon tests.
**P values are the result of Fisher's exact tests.
TABLE 2 Day 1 survey results by obesity status
Total (N = 48) BMI ≥ 30 (N = 24) BMI < 30 (N = 24)
Characteristics N (column %) N (column %) N (column %) P-value*
Self-reported limitations 28 (58.3) 16 (66.7) 12 (50.0) 0.24
Self-reported poor/fair health 25 (52.1) 15 (62.5) 10 (41.7) 0.24
Self-reported need for equipment due to medical condition 23 (47.9) 13 (54.2) 10 (41.7) 0.39
Report that shortness of breath affects quality of life 37 (77.0) 20 (83.3) 17 (70.8) 0.30
100 cigarette smoking history 24 (50.0) 12 (50.0) 12 (50.0) 1.0
Influenza vaccine receipt 24 (50.0) 13 (54.2) 11 (45.8) 0.56
Pneumonia vaccine receipt 30 (62.5) 14 (58.3) 16 (66.7) 0.55
Median (range) Median (range) Median (range) P-value**
Alcoholic drinks per day in past month 0 (0-5) 0 (0-4) 0 (0-5) 0.22
Number of children in the household 0 (0-5) 0 (0-2) 0 (0-5) 0.30
*P values are the result of Fisher's exact tests.
**P values are the result of Wilcoxon tests.
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tract disease among adults hospitalized with laboratory-confirmed
influenza. In 2011, the Advisory Committee on Immunization Practices
(ACIP) released their updated recommendations for antiviral treat-
ment. They recommended that all hospitalized patients with suspected
influenza be treated empirically, even before confirmation of influenza
status.10 The results of this study add to the existing literature that
support this treatment recommendation change by emphasizing the
importance of early antiviral treatment on improving patient out-
comes.21,22 Late antiviral treatment also appears to be an important
confounder between obesity and influenza severity, as the likelihood
of severe disease increased among obese individuals after adjustment
for treatment in all models. These findings add to previous
observations of the connection between antiviral treatment and
obesity; a 2016 paper examined antiviral treatment among hospital-
ized patients from 2010 to 2015 and found that individuals with high
risk conditions, including morbid obesity, were significantly more likely
than non-obese individuals to receive antivirals; however, the 2016
study did not evaluate timing of therapy.23
This study took place at hospitals in Detroit, Michigan, a city with
high levels of obesity and poverty.24 As expected in hospitals in an
underserved area, many participants had self-reported poor health in
addition to the need for special medical equipment and physical,
mental, or emotional limitations. Forty-six percent of patients received
health insurance from Medicaid or a Medicare/Medicaid combination
TABLE 3 Day 30 survey results by obesity status
Characteristics Total (N = 34) (%) BMI ≥ 30 (N = 20) (%) BMI < 30 (N = 14) (%) P-value*
Hospital readmission 7 (20.6) 3 (15.0) 4 (28.6) 0.41
Visit to PCP 26 (79.4) 16 (80.0) 10 (71.4) 0.69
Positive diet change 18 (52.9) 11 (55.0) 7 (50.0) 0.77
New medication prescribeda 26 (67.6) 14 (73.7) 12 (85.7) 0.67
Completed dose of new medicationb 17 (68.0) 11 (84.6) 6 (50.0) 0.10
aOne individual with obesity is missing information on new medication prescription.
bPercentages are calculated out of the number of individuals who reported having a newmedication prescribed.One obese individual who reported receiving
a new prescription had missing information on dose, so this percentage was calculated out of 13.
*P values are calculated from Fisher's exact tests.
TABLE 4 Predictive models of influenza severity among hospitalized adults treated with antivirals
ICU admission (OR, 95%CI) Admitted to ICU (N, %) (N = 7)
Univariate
associations
Multivariable
model IPW model
BMI < 30 (N = 24) 2 (8.3) 1.0 1.0 1.0
30 ≤ BMI < 40 (N = 19) 3 (13.8) 1.9 (0.3, 12.6) 2.9 (0.5, 20.9) 2.5 (0.4, 17.0)
BMI ≥40 (N = 5) 2 (11.6) 6.4 (0.8, 58.2) 7.9 (0.9, 87.1) 7.8 (0.8, 88.9)
Late antiviral treatment (N = 27) 6 (22.2) 4.13 (0.8, 42.2) 5.1 (0.9, 53.4) 5.2 (0.95, 54.3)
Lower respiratory tract disease (OR,
95%CI)
Lower respiratory tract disease (N, %)
(N = 17)
BMI <30 (N = 24) 7 (41.7) 1.0 1.0 1.0
30 ≤ BMI < 40 (N = 19) 7 (36.8) 1.4 (0.4, 5.0) 2.1 (0.5, 8.6) 3.0 (0.8, 12.3)
BMI ≥ 40 (N = 5) 3 (60.0) 3.3 (0.5, 23.5) 4.0 (0.6, 35.0) 4.0 (0.5, 37.5)
Late antiviral treatment (N = 27) 13 (48.1) 3.6 (1.1, 14.2) 4.2 (1.2, 17.7) 3.9 (1.1, 15.9)
Length of stay (Percent change, 95%
CI)
Length of stay (Median, range) (5, 1-17)
BMI <30 (N = 24) 5 (1-17) 0.0 0.0 0.0
30 ≤ BMI < 40 (N = 19) 4 (1-8) −29.2 (−49.6, −0.6) −24.1 (−46.0,
6.7)
−26.8 (−47.5,
2.1)
BMI ≥40 (N = 5) 5 (2-8) −13.6 (−49.8, 48.7) −12.0 (−48.3,
49.3)
−11.3 (−49.3,
55.3)
Late antiviral treatment (N = 27) 5 (1-17) 40.8 (2.6, 93.2) 32.5 (−4.1, 83.2) 37.2 (−.3, 88.9)
Univariate associationsmodel displays Firth corrected univariate associations.Multivariablemodel displays Firth corrected associations adjusted for BMI and
late antiviral treatment (treatment >2 days from symptom onset compared to treatment ≤2 days from onset). IPW model displays inverse probability
weighted models adjusted for age, diabetes and poor/fair self-rated health. Length of stay models were modeled as log (length of stay); results were
transformed to display percent changes.
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and an additional 4% had no insurance. Individuals with public
insurance are more likely to visit the emergency department over their
primary care physician. It is unclear whether or not this is due to
decreased access to their primary care physician, more complex
conditions that require emergency facilities, or a preference for the
hospital over outpatient clinics.25,26 In the current study, the increased
use of the emergency room among those with public insurance is
reflected in the high readmission rate (20.6%) reported from
respondents to the 30-day survey. Encouragingly, 52.9% of partic-
ipants who completed the 30-day survey reported efforts to improve
their diet or exercise routine post-hospitalization, indicating that the
hospital discharge may have the potential to be an effective time to
counsel the patient on modifiable health behaviors.
There are limitations to this analysis. The in-hospital observational
nature of the study complicated our ability to study some commonly
used severity endpoints. Reverse causation could have masked
associations between timely antiviral treatment and severe outcomes
if individuals were treated when admitted to the ICU or if lower
respiratory tract disease was already present at the time of treatment.
Lower than expected enrollment, particularly during the mild 2011-
2012 season, presented numerous difficulties. Though steroid use was
likely an important confounder of obesity and severe influenza, steroid
use could not be adjusted for due to collinearity between steroids and
other adjustment factors. A variety of other confounders were able to
be adjusted for using inverse-probability weighting despite the small
sample size; however, it is possible that residual confounding remains.
Future studies should be conducted to re-evaluate the associations
studied in this analysis, as the small sample size led to a reduction in
statistical power.
The findings of this prospective study highlight the need to
evaluate confounding from antiviral treatment timing when studying
the relationship between obesity and influenza severity. Additionally,
the association between late antiviral treatment and increased
likelihood of serious disease highlights the importance of timely
antiviral treatment. This reinforces the treatment recommendations
from the ACIP and emphasizes the need for continued evaluation of
antiviral prescription rates among hospitalized adults.
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